GeneDx Holdings Statistics
Total Valuation
GeneDx Holdings has a market cap or net worth of $2.55 billion. The enterprise value is $2.53 billion.
Important Dates
The next estimated earnings date is Tuesday, July 29, 2025, after market close.
| Earnings Date | Jul 29, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
GeneDx Holdings has 28.53 million shares outstanding. The number of shares has increased by 6.20% in one year.
| Current Share Class | 28.53M |
| Shares Outstanding | 28.53M |
| Shares Change (YoY) | +6.20% |
| Shares Change (QoQ) | +1.31% |
| Owned by Insiders (%) | 1.77% |
| Owned by Institutions (%) | 86.33% |
| Float | 19.43M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | 72.98 |
| PS Ratio | 7.50 |
| Forward PS | 6.71 |
| PB Ratio | 10.01 |
| P/TBV Ratio | 25.18 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | 1.50 |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 7.67 |
| EV / EBITDA | 278.76 |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 3.25, with a Debt / Equity ratio of 0.45.
| Current Ratio | 3.25 |
| Quick Ratio | 2.95 |
| Debt / Equity | 0.45 |
| Debt / EBITDA | 7.11 |
| Debt / FCF | n/a |
| Interest Coverage | -4.03 |
Financial Efficiency
Return on equity (ROE) is -16.61% and return on invested capital (ROIC) is -2.22%.
| Return on Equity (ROE) | -16.61% |
| Return on Assets (ROA) | -1.84% |
| Return on Invested Capital (ROIC) | -2.22% |
| Return on Capital Employed (ROCE) | -3.29% |
| Revenue Per Employee | $330,143 |
| Profits Per Employee | -$38,576 |
| Employee Count | 1,000 |
| Asset Turnover | 0.79 |
| Inventory Turnover | 9.45 |
Taxes
In the past 12 months, GeneDx Holdings has paid $186,000 in taxes.
| Income Tax | 186,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +245.41% in the last 52 weeks. The beta is 2.07, so GeneDx Holdings's price volatility has been higher than the market average.
| Beta (5Y) | 2.07 |
| 52-Week Price Change | +245.41% |
| 50-Day Moving Average | 75.47 |
| 200-Day Moving Average | 75.73 |
| Relative Strength Index (RSI) | 65.69 |
| Average Volume (20 Days) | 963,337 |
Short Selling Information
The latest short interest is 3.75 million, so 13.13% of the outstanding shares have been sold short.
| Short Interest | 3.75M |
| Short Previous Month | 3.64M |
| Short % of Shares Out | 13.13% |
| Short % of Float | 19.29% |
| Short Ratio (days to cover) | 4.35 |
Income Statement
In the last 12 months, GeneDx Holdings had revenue of $330.14 million and -$38.58 million in losses. Loss per share was -$1.41.
| Revenue | 330.14M |
| Gross Profit | 215.47M |
| Operating Income | -12.40M |
| Pretax Income | -118.33M |
| Net Income | -38.58M |
| EBITDA | 9.08M |
| EBIT | -12.40M |
| Loss Per Share | -$1.41 |
Full Income StatementBalance Sheet
The company has $159.16 million in cash and $114.84 million in debt, giving a net cash position of $44.32 million or $1.55 per share.
| Cash & Cash Equivalents | 159.16M |
| Total Debt | 114.84M |
| Net Cash | 44.32M |
| Net Cash Per Share | $1.55 |
| Equity (Book Value) | 257.41M |
| Book Value Per Share | 9.02 |
| Working Capital | 156.28M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$1.90 million and capital expenditures -$11.18 million, giving a free cash flow of -$13.08 million.
| Operating Cash Flow | -1.90M |
| Capital Expenditures | -11.18M |
| Free Cash Flow | -13.08M |
| FCF Per Share | -$0.46 |
Full Cash Flow StatementMargins
Gross margin is 65.27%, with operating and profit margins of -3.76% and -11.68%.
| Gross Margin | 65.27% |
| Operating Margin | -3.76% |
| Pretax Margin | -11.63% |
| Profit Margin | -11.68% |
| EBITDA Margin | 2.75% |
| EBIT Margin | -3.76% |
| FCF Margin | n/a |
Dividends & Yields
GeneDx Holdings does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -6.20% |
| Shareholder Yield | -6.20% |
| Earnings Yield | -1.50% |
| FCF Yield | -0.51% |
Analyst Forecast
The average price target for GeneDx Holdings is $86.14, which is -3.71% lower than the current price. The consensus rating is "Strong Buy".
| Price Target | $86.14 |
| Price Target Difference | -3.71% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 7 |
| Revenue Growth Forecast (5Y) | 17.28% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on May 4, 2023. It was a reverse split with a ratio of 0.030303:1.
| Last Split Date | May 4, 2023 |
| Split Type | Reverse |
| Split Ratio | 0.030303:1 |
Scores
GeneDx Holdings has an Altman Z-Score of 1.31 and a Piotroski F-Score of 5. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 1.31 |
| Piotroski F-Score | 5 |
